UNASSIGNED: 4047 Background: Despite a recent fall in incidence, @entity356 remains common in China. @entity1487 plus P is a standard treatment for AGC, producing response rates of 27-51% in randomized trials, although few Chinese data are available. We evaluated the efficacy and safety of replacing the @entity1487 component with X (Xeloda) as 1st-line therapy in Chinese AGC pts. METHODS: We enrolled 145 pts between @entity1178 2002 and May 2003. All had measurable AGC (WHO), and adequate Karnofsky PS, bone marrow, @entity177 . Prior radiotherapy or adjuvant chemotherapy was permitted. @entity1 received @entity416 1000 mg/m(2) orally twice daily on days 1-14 plus fractionated @entity900 20 mg/m(2) i.v. on days 1-5, every 3 weeks. RESULTS: Baseline characteristics of the 130 pts evaluable to date: 98 @entity1 , 32 @entity1 ; median age 53.7 years (range 23-80); median Karnofsky PS 80 (60-100); 82% of pts had 1 metastatic site, and 18% had >= 2, the most common being the lymph nodes (44%), liver (42%), and stomach (17%). The median treatment duration is currently 6 cycles (range 2-6). Efficacy findings are shown in the table: response rate 45% (95% CI, 36-53%). Median progression-free and overall survival have not yet been reached. There were no grade 4 and very few grade 3 adverse events (all <5%): SGPT and SGOT, @entity8566 , @entity390 , @entity391 , @entity417 , @entity294 , @entity448 , @entity2021 . Most events were easily managed with dose adjustment and/or suitable treatments, except 1 pt with @entity417 who withdrew after 2 cycles. CONCLUSIONS: X combined with fractionated P is highly active and very well tolerated as first-line treatment for AGC, with comparable results to @entity1487 /P. These results provide the rationale for randomized testing of the combination, although standard single infusion of P would enhance convenience. [Figure: see text] No significant financial relationships to disclose.

@entity416 (X) combined with @entity900 (P) as 1st-line therapy in Chinese @entity1 (pts) with advanced XXXX (AGC).

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'men'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal and hepatic functions'] @entity1178 :: ('3725', 'Gene') :: ['Jun'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU'] @entity2021 :: ('MESH:D000707', 'Disease') :: ['anaphylaxis']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
